Earlier this week, Daiichi Sankyo announced that it has launched its biosimilar trastuzumab, trastuzumab BS, referencing Herceptin, in Japan.
Earlier this week, Daiichi Sankyo announced that it has launched its biosimilar trastuzumab, trastuzumab BS, referencing Herceptin, in Japan.
In 2016, Daiichi Sankyo and Amgen entered into an exclusive biosimilar commercialization agreement. Under the agreement, Daiichi Sankyo would be responsible for filing for marketing approval as well as the distribution and commercialization of 9 biosimilars in Japan, while Amgen took over the development and manufacturing responsibilities.
The biosimilar trastuzumab was approved by the Pharmaceuticals and Medical Devices Agency on September 21, 2018, and is indicated for intravenous drip infusions at 60 mg and 150 mg for the treatment of breast cancer with human epidermal receptor 2 (HER2) overexpression, and unresectable advanced or relapsed gastric cancer with HER2 overexpression.
This marks the first biosimilar product launched by Daiichi Sankyo. “The company expects that the product will provide patients and medical professionals with various options for cancer treatment,” according to a company statement.
To date, the European market has seen the launches of 3 biosimilar trastuzumab products, sold as Ontruzant, Herzuma, and Kanjinti. While the FDA approved the first and only US-licensed biosimilar trastuzumab—Ogivri—nearly 1 year ago, it has yet to enter the US market, and no launch date has been made publicly available by sponsor Mylan.
Herceptin, developed by drug maker Roche, earned the company nearly $7,028,00 globally in 2017, making the medicine Roche’s second top-selling product.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.